| Previous Section | Index | Home Page |
12 Oct 2009 : Column 767W—continued
Thrombosis
John Smith: To ask the Secretary of State for Health when he plans to consult on the inclusion of venous thromboembolism risk assessment and prevention in the 2010-11 NHS Operating Framework. [291660]
Phil Hope: We expect the NHS Operating Framework for 2010-11 to be published later this year and we can confirm that it will include venous thromboembolism risk assessment and prevention.
John Smith: To ask the Secretary of State for Health when he expects his Department's venous thrombroembolism risk assessment model to be made available to all health professionals in the NHS through the National Programme for IT; and if he will make a statement. [291661]
Phil Hope:
We are currently looking to pilot the tool within a clinical setting and, if approved, the intention
is that the tool together with the technology could be evaluated at a number of sites. Subject to this work going ahead, the tool would then be available to download to national health service trusts at the same time as the National Institute for Health and Clinical Excellence publish their venous thrombroembolism clinical guidelines for all hospitalised patients.
Thrombosis: Hospitals
John Smith: To ask the Secretary of State for Health pursuant to the answer of 1 July 2009, Official Report, column 356W, what progress has been made in his Department's work with the Office for National Statistics to provide the requested information; and if he will make a statement. [291573]
Phil Hope: The Office for National Statistics are still working on the data which are by nature quite complex, spanning many different areas. We have received some preliminary data and are continuing to work with them to produce meaningful information on episodes of venous thromboembolism.
Treatment Centres
Mike Penning: To ask the Secretary of State for Health if he will conduct an audit of the cost of residual value payments which may be made to providers of independent sector treatment centres (ISTC) projects contracted under the (a) first and (b) second wave of the ISTC programme. [290308]
Mr. Mike O'Brien: No. There is a duty to make a residual value payment at contract expiry where the requirement exists under the terms of an independent sector treatment centres contract.
Mike Penning: To ask the Secretary of State for Health what guidance he has issued to primary care trusts on the commissioning of services from independent sector treatment centres. [290309]
Mr. Mike O'Brien: The Department has not issued primary care trusts (PCTs) with guidance on the commissioning of services from independent sector treatment centres. It is for PCTs to determine their commissioning requirements.
The Department has requested that PCTs review their capacity requirements and has provided guidance to support the competitive procurement of treatment centre services. PCTs will review contracts on a case-by-case basis and commission new services where capacity is required.
Mike Penning: To ask the Secretary of State for Health what the NHS tariff is for procedures undertaken in independent sector treatment centres. [290310]
Mr. Mike O'Brien: The national health service tariff does not apply to procedures undertaken in Wave One and Phase Two Independent Sector Treatment Centres. Providers are paid for services according to the terms and conditions of their contracts. Future contracts to provide services from treatment centres will be paid at the NHS tariff.
Mike Penning: To ask the Secretary of State for Health what plans he has for the management of the expiry of the contracts of phase one independent sector treatment centres. [290348]
Mr. Mike O'Brien: Contracts for the centrally procured wave one independent sector treatment centres are scheduled to end from 2010. Each contract will be reviewed on a case-by-case basis and new services will be commissioned where local commissioners determine that capacity is required.
Mike Penning: To ask the Secretary of State for Health what recent estimate he has made of the costs likely to be incurred by his Department in relation to its contractual obligations under phase one of the independent sector treatment centre programme after the expiry of phase one contracts. [290516]
Mr. Mike O'Brien: The total potential expiry cost (including residual value) for wave one independent sector treatment centres is approximately £200 million.
Vioxx
Mr. Amess: To ask the Secretary of State for Health what the cost to the NHS of prescribing the drug Vioxx has been in each of the last two years. [292312]
Mr. Mike O'Brien: The net ingredient cost (NIC) of prescription items written in the United Kingdom and dispensed in the community in England for 2007 and 2008, cannot be reported as the NIC was reimbursed for less than 50 prescription items. Reporting this figure could potentially identify individual patients.
Written Questions: Government Responses
Mr. Stephen O'Brien: To ask the Secretary of State for Health when he plans to answer question (a) 279209, on the composition of his Department's Applications Committee, tabled on 11 June 2009 and (b) 283263, on the NHS IT Programme, tabled on 26 June 2009. [289567]
Mr. Mike O'Brien: I refer the hon. Member to the answers I gave him on 21 July 2009, Official Report, columns 1594W and 1609W.
| Index | Home Page |